Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

WW International shares are trading higher by 79% during Tuesday's session. The company announced a new partnership with Eli ...

Eli Lilly ( LLY 2.92%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

Long-term use of tirzepatide shows sustained and significant weight loss in adults with overweight or obesity.

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Companies are developing myostatin inhibitors for GLP-1RA-related muscle loss, but some experts question their necessity.

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its ...